Sustaining and expanding behavioral health services by levying an opioid impact fee on opioid manufacturers.

HB 2072 imposes a fee of $0.01 per morphine milligram equivalent on opioid manufacturers for prescription opioids dispensed in Washington. The fee funds a new "prescription opioid impact account," with 50% dedicated to behavioral health programs for children, youth, and young adults. Funds also reimburse the state for modifying the prescription monitoring program and cover administrative costs (capped at 12% annually). Manufacturers must report quarterly opioid dispensing data to the Department of Health and pay the fee within 45 days, with penalties for late payment.